%0 Journal Article %T Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? %A Bianco, Andrea %A Campbell, Susan F. M. %J Translational Cancer Research %D 2018 %B 2018 %9 %! Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? %K %X Targeting adaptive immunity is a game changer for cancer treatment, revolutionizing lung cancer management. Chemotherapy has been the standard treatment for lung cancer (1-4) until recently when molecular targets including genes harbouring cancer-driving mutations and immune check-points have emerged as targets for new therapies (5-12). With the increasing relevance of ICIs, clinical research is required to define which combination regimens provide the greatest benefits in lung cancer patients. %U https://tcr.amegroups.org/article/view/25256 %P S103-S105 %@ 2219-6803